To evaluate 96-week virologic, immunologic, resistance and metabolic outcomes of bictegravir/emtricitabine/tenofovir alafenamide fumarate (BIC/FTC/TAF) in antiretroviral therapy (ART)-naïve people li
Note: Chi-square test was used to testify the significant difference for any outpatient visit in the past 2 weeks and any hospitalisation in the past year. T-test was used to testify the significant d
